Industry Seeks Changes In FDA Drug/Diagnostic Co-Development Model
This article was originally published in The Pink Sheet Daily
Executive Summary
AdvaMed, PhRMA urge FDA to consider that the data necessary to qualify a biomarker for predicting drug response generally is not available until Phase II or Phase III trials.